Iqirvo

®

(eye-curve-o)

Iqirvo is a new medication that has been approved in the US for treating primary biliary cholangitis (PBC) in adults who do not respond to or cannot tolerate ursodeoxycholic acid (UDCA). It provides symptom relief, particularly alleviating the persistent itching associated with PBC, and helps to slow disease progression.

Iqirvo

®

(I-curve-o)

Iqirvo is a new medication that has been approved in the US for treating primary biliary cholangitis (PBC) in adults who do not respond to or cannot tolerate ursodeoxycholic acid (UDCA). It provides symptom relief, particularly alleviating the persistent itching associated with PBC, and helps to slow disease progression.

Is Iqirvo right for you?

Determining if Iqirvo is the right choice for your treatment involves a comprehensive discussion about your medical history, current health status, and treatment goals. Iqirvo brings new hope to many living with PBC, offering a potential improvement in managing this challenging condition. As with any medication, understanding both its potential benefits and risks is crucial. For those who qualify, Iqirvo represents a significant step forward in the ongoing battle against primary biliary cholangitis.

We encourage you to contact our providers to learn more about Iqirvo and how it might fit into your treatment plan. Our healthcare professionals are here to provide detailed information and help you make an informed decision about this promising new drug. Reach out today to schedule a consultation and take the next step in managing your PBC effectively.

Make an Appointment

Site Map

PARTICIPATE IN A STUDY

Learn more about your condition, gain access to new treatments, and help advance medicine. Browse currently enrolling studies and apply to participate today!

© 2024 ARIZONA LIVER HEALTH | Site Map | Privacy Policy